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Abstract
Background: The decline in hepatitis B virus surface antigen (HBsAg) may be an early predictor of the viral efficacy of
Hepatitis B virus (HBV) therapy. The HBsAg levels obtained by different immunoassays now need comparing and the
relationships between levels of HBsAg and HBV DNA alongside HBsAg and genotype must be evaluated.
Methodology/Principal Findings: HBsAg levels were compared among 80 patients using the Abbott Architect assay, a
commercial immunoassay approved for HBsAg detection and quantitation, and three other assays derived from
immunoassays approved for HBsAg detection (manufactured by Diasorin, Bio-Rad and Roche). Good correlation was found
between the Abbot vs. Diasorin, Bio-Rad and Roche assays with narrow 95% limits of agreement and small mean
differences: 20.06 to 0.11, 20.09 log10 IU/mL; 20.57 to 0.64, 20.04 log10 IU/mL; 20.09 to 0.45, 20.27 log10 IU/mL,
respectively. These agreements were not affected by genotypes A or D. HBsAg was weakly correlated with HBV DNA,
whatever the HBsAg assay used: Abbott, r=0.36 p=0.001, Diasorin r=0.34, p=0.002; Bio-Rad r=0.37, p,0.001; or Roche
r=0.41, p,0.001. This relationship between levels of HBsAg and HBV DNA seemed to depend on genotypes. Whereas
HBsAg (Abbott assay) tended to correlate with HBV DNA for genotype A (r=0.44, p=0.02), no such correlation was
significant for genotypes D (r=0.29, p=0.15).
Conclusion/Significance: The quantitation of HBsAg in routine clinical samples is comparable between the reference assay
and the adapted assays with acceptable accuracy limits, low levels of variability and minimum discrepancy. While HBsAg
quantitation is not affected by HBV genotype, the observed association between levels of HBsAg and HBV DNA seems
genotype dependent.
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Introduction
There has been recent renewed interest in measuring serum
levels of HBsAg as a surrogate marker to predict HBsAg loss and
monitor anti-HBV therapy. During the natural history of HBV
infection, the loss of serum HBsAg is generally associated with
their seroconversion to anti-HBs, the hallmark of a successful
immunological response to HBV infection. The development of
therapies based on nucleotides and interferon in the last ten years
has dramatically improved the survival of hepatitis B virus (HBV)
infected individuals. While nucleotide analogue treatment is
constrained by the need for extended therapy, and peg-interferon
by a limited response rate, both can achieve a sustainable control
of HBV replication [1,2]. HBV therapy can induce a complete loss
of HBsAg thus indicating the control of chronic infection in some
patients. Indeed, HBsAg clearance has been reported in 11% of
HBeAg positive patients and in 8% of HBeAg negative patients
after 48 weeks of peg-interferon therapy [3]. Likewise, HBsAg
clearance was reported in 3% of HBeAg positive patients after one
year of treatment with lamivudine [4] and in 5% after 5 years
treatment with adevovir [5]. These results should be compared
with the 0.5 to 1% annual frequency of HBsAg clearance natural
occurring in untreated HBV chronic infection [6,7,8,9,10]. Some
reports have suggested that the baseline HBsAg titer may reflect
the HBV reservoir as represented by intrahepatic covalently closed
circular (ccc) DNA [11,12,13,14,15]. However, other studies failed
to confirm this association or found a positive correlation only in
patients with detectable HBeAg [16,17].
The measure of HBsAg concentration in addition to HBV DNA
and HBeAg may be a useful biological parameter to monitor HBV
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analogues [18,19,20,21]. The speed and amplitude of the decline
in HBsAg levels are suspected to be a good predictors of sustained
virological response and HBsAg loss [3,20]. Indeed, a decline in
HBsAg levels of 0.5 and 1 log10 IU/mL 12 and 24 weeks after peg-
interferon initiation, respectively, has been proposed to predict a
sustained virological response [2,3]. Alternatively, reaching HBsAg
levels below 1500 IU/mL after 12 weeks [20] or below 10 IU/mL
at the end of the treatment would also be expected to predict a
sustained response [19]. Using a cutoff at 1000 IU/ml, HBsAg
quantitation in combination with HBV DNA load may also be
able to identify infection likely to remain inactive [22]. New
algorithms including both HBsAg and HBV DNA serum levels
should be assessed with the aim of optimizing treatment strategies.
Whatever the thresholds selected, any upcoming therapeutic
recommendations based on HBsAg level would impose a
concordance among different assays concerning the measurement
of anti-HBs.
The aims of the present study were to assess the performance of
different methods to quantitate HBsAg. We sought here to
demonstrate the potential utility of slightly modified qualitative
assays to accurately measure HBsAg concentration in comparison
with the Abbott Architect assay, a commercial quantitative assay.
We also investigated the relationships between serum levels of
HBV DNA and HBsAg, and how HBV genotype could impact
this relationship and/or assay performance.
Results
Comparison of the values for HBsAg concentration
between assays
All clinical specimens provided valid and quantifiable results for
HBsAg level using the four assays. The 1/1000e dilution of the
clinical samples allowed the measurement of a value within the
range of quantitation in 92% of cases using the Abbott assay; in
79% using the Diasorin assay; 76% using Bio-Rad, and 96% using
Roche. Additional lower (undiluted or 1/20e) or higher (1/
10000e) dilutions were required for the remaining clinical samples.
The median (IQR) HBsAg concentrations were 3.68 (4.13-3.27)
log10 IU/mL with the reference Abbott assay; 3.79 (4.18-3.36)
log10 IU/mL with Diasorin; 3.75 (4.16-3.18) log10IU/mL with
Bio-Rad; and 3.49 (3.79-3.01) log10 IU/mL with Roche.
The Diasorin assay correlated well with the reference assay,
r=0.88 (p,0.001) (Fig. 1.A). The difference between 7 (9%)
paired results was above 0.5 log10IU/mL. The concordance plot
(Fig. 1.D) confirmed the strong correlation with the Abbott
method with narrow 95% limits of agreement (20.5 to 0.68) and a
weak difference mean of 0.09 log10 IU/mL.
A strong correlation was observed between Bio-Rad and Abbott
methods; r=0.93 (p,0.001) (Fig. 1.B). Ten values for HBsAg
concentration (13%) estimated by the Bio-Rad method differed
from the Abbot results by more than 0.5 log10IU/mL. According
to the Bland-Altman method, the mean difference was 0.04 log10
IU/mL, and narrow limits of agreement (20.57 to 0.65) were
achieved (Fig. 1.E).
Results obtained with the Roche assay were also highly
correlated with the Abbott assay, r=0.88 (p,0.001) (Fig. 1.C).
A difference between the two test values was above 0.5 log10 IU/
mL in 8 (10%) of the paired results. The Bland-Altman approach
(Fig. 1.F) showed a good agreement with a mean difference of
20.23 log10 IU/mL (limits of agreement: 20.9 to 0.45). There was
no proportional bias for the three assays compared to the reference
assay.
Similar comparisons were performed between the three
modified assays (data not shown). HBsAg quantitation obtained
with Diasorin vs. Roche assays presented acceptable mean
differences (0.32 log10 IU/mL,) and strong correlation (r=0.82,
p,0.0001), likewise for Bio-Rad versus Roche (mean differences
of 0.27 log10 IU/mL and r=0.91, p,0.0001) and Diasorin vs.
Bio-Rad (mean differences of 20.05 log10 IU/mL and r=0.82,
p,0.0001).
Impact of HBeAg status on HBsAg level
The median (IQR) of the log10 IU/mL HBsAg concentration
was higher in the 19 patients with detectable HBeAg than in the
61 patients with undetectable HBeAg (data not shown), 4.14
(3.45–4.78) vs. 3.62 (3.12–3.91) using the Abbott assay (p=0.03);
4.27 (3.69–4.74) vs. 3.73 (3.32–4.08) with the Diasorin (p=0.001);
4.06 (3.55–4.65) vs. 3.71 (3.11–3.98) with the Bio-Rad (p=0.031),
and 3.54 (3.08–4.43) vs. 3.49 (2.99–3.68) with the Roche
(p=0.089). Similarly, the median (IQR) HBV DNA levels tended
to be higher among individuals with detectable HBeAg 4.54 (3.17–
6.0) log10 IU/mL vs. 3.44 (2.73–4.79) log10 IU/mL (p=0.059),
data not shown).
Relationship between levels of HBV DNA and HBsAg
Overall, levels of HBsAg and HBV DNA were weakly
correlated, whatever the HBsAg assay used (Fig. 2). Taking into
account the HBeAg status (+/2), the correlations between HBsAg
and HBV DNA levels remained weak, with an identical
correlation for HBeAg-negative patients and HBeAg positive
patients of 0.33 using the Abbott assay (data not shown).
The HBsAg (log10 IU/mL, Abbott assay) to HBV DNA (log10
IU/mL) ratio was assessed on serum samples stratified on HBV
DNA level (#3 log10 IU/mL, 3–4 log10 IU/mL, 4–5 log10 IU/
mL, and .5 log10 IU/mL). The median ratio was higher in
specimens with low HBV DNA values than with high HBV DNA
values (p,0.001) (Fig. 3), median (IQR): 1.42 (1.30; 1.80); 1.03
(0.91; 1.16); 0.78 (0.71; 0.86), 0.63 (0.57; 0.72) for HBV DNA
levels #3 log10 IU/mL, 3–4 log10 IU/mL, 4–5 log10 IU/mL, and
.5 log10 IU/mL, respectively. These results suggest that the
secretion of HBsAg is more highly conserved than the HBV DNA
production among patients in whom viral replication has been
brought under control by the host.
We then analyzed the temporal evolution of the levels of HBsAg
levels measured by the Abbott assay in parallel with those of HBV
DNA in a longitudinal study of five patients with persistent HBV
infection. None of the patients had received anti-HBV drugs and
they were all negative for HBeAg. Twenty-two samples were
explored over the 2-year follow-up period. We observed a low
variation of HBsAg on sequential testing: the mean (6SD)
variation between sequential HBsAg quantitative measurements
was 16% (698) (Fig. 4). By contrast, the mean (6SD) variation of
HBV DNA between sequential measurements was 138% (6322).
Fluctuations in levels of HBsAg were generally accompanied by
those of HBV DNA.
Impact of HBV genotype on measured levels of HBsAg
The HBV genotyping was available for 69 patients. Twenty
seven subjects were infected by HBV genotype A, 5 by genotype B,
1 by genotype C, 26 by genotype D, 8 by genotype E and 2 by
genotype G. The clinical features and basic biological features
(ALT, AST, and HBV DNA) were similar among the three main
HBV-genotypes (Table 1). Similar HBsAg concentrations were
obtained by the Abbott method and the three other assays for the
genotypes A, and D (data not shown). For genotype A, the median
concentrations (log10 IU/mL) were: Abbott, 3.69 (3.36; 4.12);
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3.54 (3.11; 3.84). For genotype D they were: Abbott, 3.68 (3.23;
3.94); Diasorin, 3.76 (3.41; 4.19); Bio-Rad, 3.74 (3.24; 3.99); and
Roche, 3.50 (2.97; 3.68). For Thus the concordance between the
assays appeared unaffected by the genotypes A and D. Likewise,
the HBsAg levels were comparable among genotypes for each
method (pAbbot=0.58, pDiasorin=0.25, pBio-Rad=0.59,
pRoche=0.20), as were the medians of the HBsAg/HBV-DNA
ratio (data not shown). By contrast, the relationship between
HBsAg and HBV DNA levels did appear to be genotype
dependent. We observed a correlation between HBsAg and
HBV DNA levels for genotype A (r=0.44, p=0.02) using the
Abbot assay but not for genotypes D (r=0.29, p=0.15). The
same observation was made using the three adapted assays (Fig. 5).
Discussion
Among the several assays quantifying HBsAg that are
commercially available in Europe - Elecsys II (Roche Diagnostics),
ADVIA Centaur HBsAg assay (Bayer), Hepanostika HBsAg
(Biomerieux) [23] - the Architect assay has been the most
frequently cited in published studies. Here, the Architect HBsAg
test currently approved to monitor HBsAg concentrations in
clinical practice was used as the reference assay. This assay is
based on a chemiluminescent reaction and offers the advantage of
automated quantitation and standardization. On the other hand
the Architect assay is a single-use test format that requires
dedicated equipment using an advanced technology. While the
HBV pandemic has affected countries worldwide, the burden of
this infection is most felt in resource-limited countries. Therefore,
pressure to lower the cost of HBV antiviral therapy, including not
only the drugs against HBV but also the assays used for
monitoring infected patients is a continuous challenge. Enzyme
immunoassays are less expensive than the DNA assays used for the
genomic quantitation of HBV in serum. In addition, assays using
colorimetric detection are less technically demanding than
chemiluminescent immunoassays with respect to required facilities
and instrumentation. Finally, most of these tests use a microplate
format and may be performed manually.
In our study, the quantitation of HBsAg levels in routine clinical
samples by different test systems appeared overall to be accurate,
Figure 1. Comparison of the AgHBs concentrations between Abbott and Diasorin, Bio-Rad, Roche assays. Linear regression analysis of
HBsAg levels (expressed in log10 IU/ml) obtained by (A) Abbott vs. Diasorin, (B) Abbott vs. Bio-Rad, Abbott vs. Roche immunoassays, and Bland-
Altman plot of HBsAg level differences between (D) Abbott and Diasorin, (E, F) Abbott and Bio-Rad, (G) Abbott and Roche immunoassays. The
horizontal solid lines indicate the mean titer difference values, the dashed lines represent the 61.96-SD limits from the means, and diagonal solid
lines are the linear regression lines.
doi:10.1371/journal.pone.0032143.g001
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the reference assay. Thus the HBsAg level appears as a robust
biological parameter that can be accurately measured by different
ELISA assays. While most enzyme immunoassays devoted to
HBsAg detection are not approved for HBsAg quantitation, they
may be used for this purpose. The lower limit of quantitation was
found to be close to cutoffs obtained with the chemiluminescent
immunoassays and was adequate to efficiently quantify all serum
samples tested in our study. In addition, this lower limit of
quantitation is markedly below the clinically significant threshold
of 10 IU/mL proposed by Brunetto et al. [19]. Although the
colorimetric assays used in our study require the establishment of a
calibrated curve, they do offer several advantages over the
Architect test, notably, they are simple, inexpensive, and have
analytical performance characteristics similar to those obtained
with the commercial HBsAg quantitative assay. Nevertheless, the
differences observed between assays in the Bland-Altman plots
suggest that the same assay should be used throughout the whole
period of therapeutic monitoring for any one patient.
The measurement of HBsAg levels would be particularly well
adapted to the treatment of HBeAg negative patients. HBeAg-
negative hepatitis variants with mutations in the precore or basic
core promoter regions are frequent among chronic HBV carriers
in Mediterranean countries, and represent the majority of
chronically infected patients in our hospital (89%, personal data).
HBsAg levels are lower in HBeAg negative than in HBeAg positive
samples, as previously reported [24]. This observation is in line
with a previous report indicating that pre-S deletion involved in
HBeAg negative HBV infection decreases the synthesis of small
surface antigens [25].
In the current transversal study patients were explored in
different phases of HBV infection without stratification in the
various clinical presentation of chronic hepatitis B. This limits the
possibilities to fully characterize the complex association of HBsAg
and HBV DNA levels during the natural history of chronic
hepatitis B. However, our results indicated that the poor
correlation reported between HBsAg and HBV DNA levels
Figure 2. Correlation of HBsAg (log IU/mL) and HBV DNA (log IU/mL). (A) Abbott, (B) Diasorin, (C) Bio-Rad, (D) Roche immunoassays.
doi:10.1371/journal.pone.0032143.g002
Figure 3. Plots of Log10 IU/ml HBV-DNA/HBsAg ratio by levels
of HBV replication.
doi:10.1371/journal.pone.0032143.g003
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repeated measures of HBsAg and HBV DNA levels, we observed
stable HBsAg concentration in the absence of significant HBV
DNA and ALT variations. Previous studies have reported that
fluctuations in HBsAg level are associated with changes in HBV
DNA level [11,26].The highest correlations between HBV DNA
and HBsAg levels are found in early phases of infection, during
acute infection, immune clearance and HBeAg positive hepatitis B
persistent infection [17,27,28]. In advanced phases of infection,
the level of replication is generally low and associated with the
production of much more defective viral HBsAg particles secreted
as noninfectious filamentous or spherical subviral particles [25,30].
Hence, in later phases of infection when the ratio of HBsAg/HBV-
DNA is low, the association between HBsAg production and HBV
DNA replication seems weakest or ‘‘disconnected’’ [19].
Our results from all four assays used in this study demonstrated
that there is no impact of HBV genotype on HBsAg quantitation
or on the ratio of HBsAg/HBV DNA. However, the efficiency of
the HBV DNA template to produce HBsAg may be differently
affected by HBV genotype diversity. Indeed, we observed a weak
correlation between HBsAg production and HBV DNA replica-
tion for genotype A but not for genotype D. Based on in vitro
observations of HBV DNA replication, genotype A virus appears
to have a lower replication rate by comparison with other
Figure 4. Temporal evolution of HBsAg and HBV DNA in five patients with persistente HBV infection. HBsAg log10 IU/ml (& and solid
line), HBV DNA (n and dotted line).
doi:10.1371/journal.pone.0032143.g004
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reported at baseline for HBV genotypes A and D by comparison
with other genotypes [19]. By contrast with our results and using
the same PCR method, Wursthom et al. [21] recently reported a
correlation between HBsAg and HBV DNA for genotype D, but
not for genotype A. Such discrepancy between studies could be
explained at least partly by clinical difference in the population of
patients that we did not take into account. Further studies are
required to better characterize the association of HBsAg serum
levels with the various clinical settings of chronic HBV infection.
In conclusion, the quantity of HBsAg can be efficiently
measured using commercially available assays developed for
qualitative assessment. These methods are appropriate for the
monitoring of patient response to antiviral therapy. Some highly
cost-effective assays, such as colorimetric assays, are applicable in
resource-constrained countries. To ensure a better use of HBsAg
quantitation during therapy, studies are needed to establish
clinically relevant thresholds according to HBV genotype, HBeAg
status, HBsAg/HBV DNA ratio and clinical stage of HBV
persistent infection.
Materials and Methods
Patients
The study included 80 adult patients chronically infected by
HBV and untreated for HBV infection at the time of sampling.
The study was approved by the institutional ethics research
committee and patients provided written informed consent.
Subjects included were 51 men and 29 women with a median
age of 44 years. The median (interquartile range-IQR) HBV DNA
serum level was 3570 (628-114500) IU/mL. The serum concen-
trations of alanine amino transferase (ALT) and aspartate
aminotransferase (AST) were 31 (21–62) IU/L and 31 (22–50.5)
IU/L respectively. Nineteen patients (24%) were HBeAg positive.
Among HBeAg negative patients, twenty one (26%) had a status of
inactive carrier with persistently normal ALT and HBV DNA
below 2000 IU/mL. Twenty seven clinical serum specimens
collected from five patients included in the study were used for
sequential HBV viral load and HBsAg testing over a two-year
period. These patients were negative for HBeAg with persistently
normal ALT and HBV DNA ranging from 594 to 664 000 IU/
mL at baseline.
Standard HBsAg preparation
The standard HBsAg consisted of a reference preparation of
plasma purified HBsAg purchased from Biokit (Barcelona, Spain)
that contained Ayw and Adw HBsAg in equal quantities. This
standard preparation was serially diluted in a pool of HBsAg
negative serum samples in order to obtain concentrations between
0.03 and 250 IU/mL. The dilutions of the reference HBsAg were
used to investigate the range of linearity of the assays and to
establish standard curves [30].
Table 1. Clinical and basic features for the two main genotypes.
Genotype A (n=27) Genotype D (n=26) Kruskall Wallis
Median (IQR) Median (IQR) P value
ALT (IU/L) 29.50 (22.00–43.00) 31.00 (25.00–90.00) 0.37
AST (IU/L) 31.50 (25.00–68.00) 34.00 (21.00–44.00) 0.68
HBV DNA (log10 IU/mL) 3.37 (2.53–5.82) 3.45 (3.03–4.32) 0.60
HBsAg Abbott (log10 IU/mL) 3.69 (3.36–4.12) 3.68 (3.23–3.94) 0.57
HBsAg Diasorin (log10 IU/mL) 4.04 (3.39–4.26) 3.76 (3.41–4.19) 0.25
HBsAg Bio-Rad (log10 IU/mL) 3.77 (3.30–4.12) 3.74 (3.24–3.99) 0.59
HBsAg Roche (log10 IU/mL) 3.54 (3.11–3.84) 3.50 (2.97–3.68) 0.41
Results for genotypes B (n=3), C(n=1), E (n=8) and G (n=2) are not presented.
doi:10.1371/journal.pone.0032143.t001
Figure 5. Correlation of HBsAg (log10 IU/mL) and HBV DNA (log10 IU/mL). (A) VHB genotype A, Abbott r=0.44, p=0.02; Diasorin r=0.49,
p=0.01; Bio-Rad r=0.46, p=0.02; Roche r=0.47, p=0.02; (B) genotype D, Abbott r=0.29, p=0.15; Diasorin r=0.05, p=0.81; Bio-Rad r=0.30,
p=0.14; Roche r=0.38, p=0.05.
doi:10.1371/journal.pone.0032143.g005
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Three different automated immunoassays were compared with
the Architect HBsAg QT assay, a commercial quantitative assay
developed by Abbott laboratories (Abbott, Chicago, IL).
N The Abbott assay is a chemiluminescent microparticle immu-
noassay approved in Europe for the detection and quantitation
of HBsAg. It is internally calibrated using the World Health
Organization standard for HBsAg [31], and measures HBsAg
concentrations within the range of 0.05 to 250 IU/mL. The
manufacturer recommends a 1:500 dilution of the test samples.
Samples with HBsAg levels above or below this range require a
lower or greater dilution in the manufacturer’s diluent to bring
them into the range of the calibration curve. The lower limit of
detection of this assay is 0.05 IU/mL.
N The ETI-MAK-4 assay (DiaSorin, Turin, Italy) is a conven-
tional enzyme immunoassay using 96 well microplates. We
performed this assay on a Triturus automate (Grifols,
Barcelona, Spain). The lower limit of detection is 0.05 IU/
mL and 0.03 PEI U/mL. Optical densities were reported on a
standard curve to calculate the values expressed in IU/mL.
N The Monolisa HBs Ag ULTRA assay (Bio-Rad Laboratories,
Redmond, WA) is another conventional enzyme immunoassay
using 96 well microplates. This assay was run on an EVOLIS
Twin Plus automate (Bio-Rad Laboratories). The lower limit of
detection with this assay is 0.50 pg/mL. Optical densities were
reported on a standard curve to obtain the results in IU/mL.
N The Roche HBsAg II assay on the Cobas e411 system is a
chemiluminescent microparticle immunoassay (Roche Diag-
nostics GmbH, Mannheim, Germany) used for HBsAg
detection. The lower limit of detection of this assay is
0.1 IU/mL and 0.1 PEI U/mL. The chemiluminescent
reaction measured in relative light units was reported on a
standard curve to calculate values expressed in IU/mL.
Patient samples preparations were diluted in a pool of
decomplemented sera negative for HBsAg, anti-HBc and anti-
HBs antibodies (1:1000 dilution) to assess HBsAg concentration
using the three modified assays. Samples with results falling
beyond the linear range of the standard curve were retested in
lower or greater dilutions. Apart from the dilution step, HBsAg
analyses were performed in accordance with the manufacturer’s
recommendations.
Calibration curves, ranges of quantitation and
reproducibility
The linear range for HBsAg concentration measurements for
the adapted Diasorin, Bio-Rad and Roche HBsAg quantitative
assays was assessed using serial dilutions of the standard. The
following quantitation ranges were retained: 0.24 to 62.5 IU/mL
for Diasorin and Bio-Rad assays and 0.24 to 125 IU/mL for the
Roche assay. A strong linear relationship between the optical
density or relative light units and HBsAg concentration was
observed in the three assays, (r
2.0.999, data not shown). The
lower limit of quantitation was set as the lowest point of the
standard dilution used for the calibration curve. Replicate aliquots
of the standard preparation (1.8 log10 IU/ml) were also used to
evaluate the assay precision by calculating the percent coefficient
of variation (%CV) for log10-transformed data over nine separate
runs. Mean %CV were 9.6% for Abbott, 13.2% for Diasorin,
10.0% for Bio-Rad, and 4.2% for Roche assays (data not shown).
HBV DNA viral load
HBV DNA viral load was measured using the CobasAmpli-
Prep/CobasTaqMan HBV Test, v2.0 (Roche Diagnostics GmbH,
Mannheim, Germany). The HBV DNA quantitation range was 20
to 1.7.10
8 IU/mL with the correlation coefficient of the standard
curve consistently exceeding 0.990. In this assay, 4.86 copies/mL
equaled 1 IU/mL.
HBV genotyping
HBV genotyping was obtained for 35 patients. DNA was
extracted from 200 ml of serum using the QIAampH DNA Blood
Mini Kit (Qiagen GmbH, Hilden) according to the manufacturer’s
protocol. HBV genotype was determined using the TRUGENEH
HBV Genotyping Kit for use with the OpenGeneH DNA
Sequencing System (Siemens Healthcare Diagnostics Inc, Tarry-
town, USA). The TRUGENE HBV Module 1.0 contains all the
necessary software components to perform HBV genotyping
analysis. The query sequence is in turn compared to the consensus
sequences of genotypes A through to G in the TRUGENE HBV
Module of the OpenGene system software in order to determine
the HBV genotype of the sample (Mutations in both Sag and RT/
Pol regions are also detected and reported).
Statistical Analysis
A logarithmic transformation was applied to HBsAg and HBV
DNA concentrations. Continuous variables were expressed as
medians (IQR).
The agreement and relationship between the Abbott Architect
assay and the three modified assays were studied using Bland-
Altman Plots and Spearman’s correlation coefficients.
The impact of HBeAg status on HBsAg and HBV DNA levels
was analyzed using Wilcoxon Mann Whitney test.
The association between HBV DNA replication and HBsAg
production was assessed using the Spearman’s correlation
coefficient, and by analyzing the ratio of HBsAg (log10 IU/mL),
measured by the Architect assay, to HBV DNA (log10 IU/mL)
with the Jonckheere-Terpstra test.
The impact of genotype on HBsAg and HCV DNA levels was
assessed using a Wilcoxon Mann Whitney test.
Statistical tests were two-sided and a p-value#0.05 was
considered statistically significant. The statistical software SAS
version 9.2 (SAS Institute, Cary, N.C.; proc npar1way, proc
univariate) was used for the statistical analyses.
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